参考文章(347)
T Lam, K L Trimpe, P J Marks, W P Carney, S J McKenzie, J Morgan, D L Panicali, Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. ,vol. 4, pp. 543- 548 ,(1989)
R. Sadasivan, R. Morgan, S. Jennings, M. Austenfeld, P. Van veldhuizen, R. Stephens, M. Noble, Overexpression of Her-2/Neu may be an Indicator of Poor Prognosis in Prostate Cancer The Journal of Urology. ,vol. 150, pp. 126- 131 ,(1993) , 10.1016/S0022-5347(17)35413-7
A D Seidman, L Norton, J Baselga, P P Rosen, HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. ,vol. 11, pp. 43- 48 ,(1997)
L Norton, Evolving concepts in the systemic drug therapy of breast cancer. Seminars in Oncology. ,vol. 24, ,(1997)
J C Sarup, H M Shepard, B M Fendly, M T Lipari, K L King, A Ullrich, R M Johnson, M A Napier, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth regulation. ,vol. 1, pp. 72- 82 ,(1991)
C. R. King, I. Borrello, F. Bellot, P. Comoglio, J. Schlessinger, Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. The EMBO Journal. ,vol. 7, pp. 1647- 1651 ,(1988) , 10.1002/J.1460-2075.1988.TB02991.X
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)